BiotechTV

•

Channel • 5 Shows

Life Sciences

Life Sciences

Updated 25 Jun
Life Sciences

Life Sciences

Updated 23 Jul
Life Sciences

Life Sciences

Updated 5 Mar
Life Sciences

Life Sciences

Updated 2 Feb
Life Sciences

Life Sciences

Every two weeks

27 Jul

U.S. Science Summit: Biotech veteran Harvey Berger presents an overview of the history of Kendall Square and what is at stake to keep it a leader in life sciences

Dr. Berger, who founded Ariad Pharmaceuticals here in 1991, describes Kendall's transition from candy factories, to Polaroid, to what it is today.
25 Jun

Episode 7: Perceptive Advisors' Joe Edelman discusses how biotech investing has changed over his extensive career, and his thoughts on running an investment firm

He describes to Matt how the market has become more efficient since he started in the 1990's. He shares his perspective on single-asset vs pipeline companies, and today's M&A dynamic. Plus, his goal of being unbiased as an investor and how he tries to create an environment at Perceptive where that style is instilled in his analysts.
20 Mar

Biotech CEOs discuss the importance of culture, getting through challenging times, their policy wishlist, and how they are proud of the ways our industry gives back

MassBio President & CEO Kendalle Burlin O'Connell moderates a discussion with Zag Bio CEO Jason Cole and Altido Therapeutics CEO Chip Clark about running early stage companies and what advice they have for new CEOs. They offer advice about what it will take to keep our ecosystem globally competitive.
22 Apr

Replimune's Chairman discusses FDA's polarizing decision to not approve the company's melanoma treatment after a new review. He says they have filed a FOIA request to learn more about FDA's process

Philip Astley-Starke describes the timeline of development of this oncolytic immunotherapy, his impression of FDA's review process and decisions around it, and the status of where the treatment stands today.
26/06/2025

William Blair biotech analyst Andy Hsieh takes stock of the obesity space after attending the 2025 American Diabetes Association's (ADA's) 85th Scientific Sessions in Chicago

He discusses data presented at #ADA25 including Eli Lillys Orforglipron and Bimagrumab, Novo Nordisk's CagriSema, and Amgen's MariTide. Plus, thoughts on Viking's program as it enters phase 3.
31 Mar

CellCentric has kicked off dosing of its first registration-supporting study for the oral p300/CBP inhibitor inobrodib in multiple myeloma today

The first patient was dosed in DOMMINO-1, a Phase 2 open-label, single-arm study enrolling 100 adult patients across clinical sites in the UK and U.S.. It could potentially offer an accelerated approval opportunity if it reaches a high enough response rate.
17 Feb

From Oxford: Professor Matthew Wood describes the Oxford-Harrington Rare Disease Centre, a transatlantic effort to accelerate drug development for rare diseases

He highlights the centre's Scholars program, which researchers anywhere can apply for and funds ten new drug development programs each year. Plus the centre's accelerator program and plans for a rare disease investment fund. He also discusses how regulatory changes at places like MHRA can help the rare disease community.
17 Mar

Earli, which raised $105M in two rounds, is developing 'Cancer-Activated Promoters' that are set off by cancer-specific transcription factors and turn tumor cells into therapeutic payload factories

Co-Founder & CEO Cyriac Roeding and Co-Founder & CSO David Suhy describe the science behind this approach and explain how AI is helping they move closer to the clinic. The first IND filing is scheduled to be late '26 or early '27.
25 Mar

Christian Tidona's BioMed X and Michal Preminger are launching BioMed X Venture Labs in Cambridge, MA to create 'build to solve' startups with partners

Michal Preminger will lead BioMed X Venture labs as CEO, and it will partner with pharma, foundations, and VCs to build mission driven companies.
19 Mar

From London: iOnctura is developing its allosteric PI3Kδ for uveal melanoma - an indication that has seen progress but still has much unmet need

From Syncona's Capital Markets Day, Founder and CEO Catherine Pickering walks us through the science of roginolisib and describes the current landscape for uveal melanoma. She discusses her phase 2, which is approaching a key readout.

BiotechTV covers the biotechnology sector through news, stories, podcasts, and educational videos.

Website

BiotechTV

Top Shows

U.S. Science Summit: Biotech veteran Harvey Berger presents an overview of the history of Kendall Square and what is at stake to keep it a leader in life sciences

Episode 7: Perceptive Advisors' Joe Edelman discusses how biotech investing has changed over his extensive career, and his thoughts on running an investment firm

Biotech CEOs discuss the importance of culture, getting through challenging times, their policy wishlist, and how they are proud of the ways our industry gives back

Replimune's Chairman discusses FDA's polarizing decision to not approve the company's melanoma treatment after a new review. He says they have filed a FOIA request to learn more about FDA's process

William Blair biotech analyst Andy Hsieh takes stock of the obesity space after attending the 2025 American Diabetes Association's (ADA's) 85th Scientific Sessions in Chicago

CellCentric has kicked off dosing of its first registration-supporting study for the oral p300/CBP inhibitor inobrodib in multiple myeloma today

From Oxford: Professor Matthew Wood describes the Oxford-Harrington Rare Disease Centre, a transatlantic effort to accelerate drug development for rare diseases

Earli, which raised $105M in two rounds, is developing 'Cancer-Activated Promoters' that are set off by cancer-specific transcription factors and turn tumor cells into therapeutic payload factories

Christian Tidona's BioMed X and Michal Preminger are launching BioMed X Venture Labs in Cambridge, MA to create 'build to solve' startups with partners

From London: iOnctura is developing its allosteric PI3Kδ for uveal melanoma - an indication that has seen progress but still has much unmet need

About

BiotechTV

Top Shows

Top Episodes

About